VAXCYTE, INC. Capital Expenditures
VAXCYTE, INC. (PCVX) reported Capital Expenditures of $6.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-05
- VAXCYTE, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $4.32M, a 138.49% increase year-over-year.
- VAXCYTE, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $2.11M, a 61.15% decline year-over-year.
- VAXCYTE, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $2.65M, a 34.00% decline year-over-year.
- VAXCYTE, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $3.82M, a 22.70% decline year-over-year.
- VAXCYTE, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $13.71M, a 38.85% decline from fiscal 2024.
- VAXCYTE, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $22.43M, a 39.63% increase from fiscal 2023.
- VAXCYTE, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $16.06M, a 174.99% increase from fiscal 2022.
- VAXCYTE, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $5.84M, a 10.89% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $4.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $6.43M 10-Q · filed 2026-08-05 | $9.08M derived: sum of 3 quarters · filed 2026-08-05 | $12.90M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $2.11M 10-Q · filed 2026-05-06 | $4.76M derived: sum of 2 quarters · filed 2026-05-06 | $8.59M derived: sum of 3 quarters · filed 2026-05-06 | $10.40M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $6.48M derived: sum of 2 quarters · filed 2026-02-24 | $8.29M derived: sum of 3 quarters · filed 2026-08-05 | $13.71M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $3.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.63M derived: sum of 2 quarters · filed 2026-08-05 | $11.06M 10-Q · filed 2025-11-04 | $15.08M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $7.24M 10-Q · filed 2026-08-05 | $11.26M derived: sum of 3 quarters · filed 2026-08-05 | $16.20M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $5.42M 10-Q · filed 2026-05-06 | $9.45M derived: sum of 2 quarters · filed 2026-05-06 | $14.39M derived: sum of 3 quarters · filed 2026-05-06 | $22.17M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.97M derived: sum of 2 quarters · filed 2026-02-24 | $16.75M derived: sum of 3 quarters · filed 2026-02-24 | $22.43M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $4.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $12.73M derived: sum of 2 quarters · filed 2025-11-04 | $18.41M 10-Q · filed 2025-11-04 | $23.66M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $7.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $13.46M 10-Q · filed 2025-08-06 | $18.71M derived: sum of 3 quarters · filed 2026-02-24 | $26.05M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $5.68M 10-Q · filed 2025-05-07 | $10.93M derived: sum of 2 quarters · filed 2026-02-24 | $18.27M derived: sum of 3 quarters · filed 2026-02-24 | $16.13M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $12.59M derived: sum of 2 quarters · filed 2026-02-24 | $10.45M derived: sum of 3 quarters · filed 2026-02-24 | $16.06M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $7.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $5.20M derived: sum of 2 quarters · filed 2024-11-05 | $10.81M 10-Q · filed 2024-11-05 | $11.95M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | -$2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.47M 10-Q · filed 2024-08-06 | $4.61M derived: sum of 3 quarters · filed 2025-02-25 | $5.45M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-03-31 | $5.61M 10-Q · filed 2024-05-08 | $6.75M derived: sum of 2 quarters · filed 2025-02-25 | $7.59M derived: sum of 3 quarters · filed 2025-02-25 | $8.53M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2022-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.98M derived: sum of 2 quarters · filed 2025-02-25 | $2.92M derived: sum of 3 quarters · filed 2025-02-25 | $5.84M 10-K · filed 2025-02-25 | $5.85M 10-K · filed 2023-02-27 |
| 2022-09-30 | $843.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $1.78M derived: sum of 2 quarters · filed 2023-11-06 | $4.70M 10-Q · filed 2023-11-06 | $6.08M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $938.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.86M 10-Q · filed 2023-08-08 | $5.24M derived: sum of 3 quarters · filed 2024-02-27 | $6.96M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $2.92M 10-Q · filed 2023-05-08 | $4.30M derived: sum of 2 quarters · filed 2024-02-27 | $6.02M derived: sum of 3 quarters · filed 2024-02-27 | $8.23M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $3.10M derived: sum of 2 quarters · filed 2024-02-27 | $5.31M derived: sum of 3 quarters · filed 2024-02-27 | $6.55M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $3.93M derived: sum of 2 quarters · filed 2022-11-07 | $5.17M 10-Q · filed 2022-11-07 | $5.89M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.45M 10-Q · filed 2022-08-08 | $4.18M derived: sum of 3 quarters · filed 2023-02-27 | $4.21M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $1.25M 10-Q · filed 2022-05-09 | $1.97M derived: sum of 2 quarters · filed 2023-02-27 | $2.00M derived: sum of 3 quarters · filed 2023-02-27 | $2.05M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2020-12-31 | $722.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $751.00K derived: sum of 2 quarters · filed 2023-02-27 | $806.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.16M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $84.00K derived: sum of 2 quarters · filed 2021-11-10 | $433.00K 10-Q · filed 2021-11-10 | $1.39M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $404.00K 10-Q · filed 2021-08-11 | $1.36M derived: sum of 3 quarters · filed 2022-02-28 | $1.42M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $349.00K 10-Q · filed 2021-05-11 | $1.30M derived: sum of 2 quarters · filed 2022-02-28 | $1.36M derived: sum of 3 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $953.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.01M derived: sum of 2 quarters · filed 2022-02-28 | $1.20M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $242.00K 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $182.00K 10-Q · filed 2020-08-12 | ||||
| 2018-12-31 | $1.77M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |